Prepared as background for the OHE Commission on Competition, this paper provides an overview of the published literature detailing the links between quality and competition in health care systems. It finds that most empirical research to date has focused on aspects of competition and quality in the hospital sector, rather than GP/outpatient care.
Because health care resources always are scarce, decisions about what (and what not) to pay for cannot be avoided. Deciding how to value health and aspects of health care continue to be the subject of much debate. In this Briefing, Prof Donaldson takes a thorough look at the potential role of the willingess to pay (WTP) approach as a means for valuing the intangibles in health care. He examines whether more explicit monetary valuation of benefits, through elicitation of patients’ and the public’s willingness to pay, are not only useful, buy feasible and defensible in
This paper investigates how the increased rate of Quality and Outcomes Framework (QOF) payments implemented on 1 April 2005 affects Scottish general practitioners’ (GPs) intrinsic, extrinsic and overall motivation. A first difference method is used to model GPs’ intrinsic and overall motivation. The main finding is that the increased QOF payment effectively motivated GPs' health care supply, but it also 'crowded out' GPs' intrinsic motivation.
Shah, K., Sussex, J., Hernandez-Villafuerte, K. and Garau, M., Rotolo, D., Hopkins, M.M., Grassano, N., Crane, P., Lang, F., Hutton, J., Pateman, C., Mawer, A., Farrell, C. and Sharp, T.
As earlier OHE research has demonstrated, sources of funding for medical research—public, charity and private sector—are complementary, not duplicative. The three sectors also differ in their approaches. As a result, decreased funding from one would not only reduce the overall financing available, but also change the nature of the research effort overall. This is a concern given that austerity in government spending in the UK is likely to continue for some time. This report produced by OHE and SPRU at the University of Sussex for Cancer Research UK explores two sets of questions: 1.
The speaker for the OHE's 16th Annual Lecture was Sir Mike Richards, National Clinical Director for Cancer and End of Life Care in England's Department of Health.
In his presentation, Prof Richards addressed five questions about the NHS achieving world class outcomes in cancer: (1) What would ‘world class’ look like (2) What measures are appropriate? (3) Where are we now? (4) Why are England's outcomes below the best? and (5) What do we need to do to close the gap?
Shah, K., Praet, C., Devlin, N., Sussex, J., Appleby, J. and Parkin, D.
The appraisal of health care technologies by the UK’s National Institute for Health and Clinical Excellent (NICE) focuses on cost effectiveness, usually measured in terms of incremental cost per quality adjusted life year (QALY) gained. According to the findings presented in this Research Paper, however, cost effectiveness does not appear to be the dominant consideration in NHS decisions about resource allocation.
Continuing concern about the fiscal deficit makes it likely that government funding of health and medical research will remain under scrutiny. This OHE Consulting study, commissioned by Cancer Research UK, explores the interdependence between publicly funded and charity funded medical research. In particular, it focuses on whether and how changes in the levels of government funding can affect private funding for charities, medical research and the UK economy as a whole.
The UK’s National Clinical Assessment Agency (NCAS) is designed specifically to provide advice on performance issues, on request, to NHS organisations employing or contracting with doctors, pharmacists, and dentists. Currently, the NCAS is financed from central NHS funds, not from charges to NHS organisations. By 2013, however, the NCAS is to become self-funding.
Professor Ben Martin (Science and Technology Policy Studies at SPRU, University of Sussex) defines science policy research as ‘economic, policy, management and organisational studies of science, technology and innovation (STI) with a view to providing useful inputs to decision-makers concerned with policies for and the management of STI’. The field is important because STI is important: it is a source of progress, a major contributor to the wealth of nations, provides the basis for new goods and services and for new capabilities, and contributes to changes in the quality of life and t